Search

Almirall SA

Abrir

SetorSaúde

12.9 -0.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.82

Máximo

12.92

Indicadores-chave

By Trading Economics

Rendimento

13M

21M

Vendas

-14M

260M

P/E

Médio do Setor

60.7

88.032

EPS

0.1

Margem de lucro

8.059

Funcionários

2,026

EBITDA

12M

66M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+7.75% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-80M

2.6B

Abertura anterior

13.05

Fecho anterior

12.9

Sentimento de Notícias

By Acuity

34%

66%

88 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Almirall SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de dez. de 2025, 22:20 UTC

Grandes Movimentos do Mercado

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 de dez. de 2025, 17:31 UTC

Grandes Movimentos do Mercado

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 de dez. de 2025, 16:30 UTC

Grandes Movimentos do Mercado

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 de dez. de 2025, 15:19 UTC

Grandes Movimentos do Mercado

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 de dez. de 2025, 15:17 UTC

Grandes Movimentos do Mercado

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 de dez. de 2025, 14:37 UTC

Grandes Movimentos do Mercado

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

31 de dez. de 2025, 21:13 UTC

Aquisições, Fusões, Aquisições de Empresas

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 de dez. de 2025, 20:40 UTC

Conversa de Mercado

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 de dez. de 2025, 20:22 UTC

Conversa de Mercado

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 de dez. de 2025, 19:50 UTC

Conversa de Mercado

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 de dez. de 2025, 19:31 UTC

Conversa de Mercado

Precious Metals Cap Off Record Runs -- Market Talk

31 de dez. de 2025, 18:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

31 de dez. de 2025, 18:50 UTC

Conversa de Mercado

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 de dez. de 2025, 17:17 UTC

Conversa de Mercado

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 de dez. de 2025, 17:16 UTC

Grandes Movimentos do Mercado

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 de dez. de 2025, 17:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

31 de dez. de 2025, 17:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 de dez. de 2025, 15:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 de dez. de 2025, 15:54 UTC

Conversa de Mercado

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 de dez. de 2025, 15:02 UTC

Grandes Movimentos do Mercado

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 de dez. de 2025, 14:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 de dez. de 2025, 14:20 UTC

Conversa de Mercado

Crude Futures On Track to End the Year With Losses -- Market Talk

31 de dez. de 2025, 13:46 UTC

Conversa de Mercado

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 de dez. de 2025, 13:01 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 de dez. de 2025, 11:10 UTC

Conversa de Mercado

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 de dez. de 2025, 10:46 UTC

Conversa de Mercado

Euro on Track For Strong Annual Performance -- Market Talk

31 de dez. de 2025, 10:25 UTC

Conversa de Mercado

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 de dez. de 2025, 10:23 UTC

Conversa de Mercado

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 de dez. de 2025, 09:33 UTC

Conversa de Mercado

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Almirall SA Previsão

Preço-alvo

By TipRanks

7.75% parte superior

Previsão para 12 meses

Média 13.9 EUR  7.75%

Máximo 14.5 EUR

Mínimo 13.3 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Almirall SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

9.76 / 10.2Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

88 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat